Carfilzomib: A Promising Proteasome Inhibitor For the Treatment of Cervical Cancer

Medical (Gynecology)

Cervical cancer is still a major health problem around the world. It is the fourth most common cancer in women. Even though screening and vaccination have gotten better, there are still not many good treatments for advanced and recurrent cervical cancer. Platinum-based chemotherapy works only a little and causes a lot of resistance to build up. Proteasome inhibitors are a new type of drug that has changed the way we treat blood cancers, especially multiple myeloma. Carfilzomib, a second-generation irreversible proteasome inhibitor, has exhibited encouraging preclinical efficacy across multiple solid tumors. This thorough review brings together the latest research on carfilzomib and other proteasome inhibitors that could be used to treat cervical cancer. It looks at how these drugs work at the molecular level, how well they work in preclinical studies, how they could be used in combination with other drugs, how they might become resistant, and what this means for real-world use. Although direct clinical evidence for carfilzomib in cervical cancer is scarce, preclinical studies involving related proteasome inhibitors exhibit substantial anti-tumor activity via various mechanisms, including the induction of apoptosis, cell cycle arrest, and increased sensitivity to conventional chemotherapy. The ubiquitin-proteasome system has been confirmed as a viable therapeutic target in cervical cancer, with combination strategies demonstrating significant potential for addressing drug resistance and enhancing therapeutic efficacy.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.